Actively Recruiting
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
Led by Medical University of Warsaw · Updated on 2024-08-15
40
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
CONDITIONS
Official Title
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with diagnosed RASopathy
- Patient with diagnosed hypertrophic cardiomyopathy
- Signed informed consent
You will not qualify if you...
- Contraindications to propranolol (drug hypersensitivity, atrioventricular block, severe bradycardia)
- Contraindications to disopyramide (drug hypersensitivity, WPW syndrome, atrioventricular block, QT prolongation)
- Contraindications to trametinib (drug hypersensitivity)
- Lack of consent from the child's guardians to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Paediatrics, The Medical University of Warsaw, Poland
Warsaw, Poland, 02-091
Actively Recruiting
Research Team
M
Maciej Kołodziej, MD
CONTACT
H
Halszka Kamińska, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here